Literature DB >> 28237317

A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy.

Philip M Lam1, Jessica Carlsen1, Marco I González2.   

Abstract

In this study, we used the pilocarpine model of epilepsy to evaluate the involvement of calpain dysregulation on epileptogenesis. Detection of spectrin breakdown products (SBDPs, a hallmark of calpain activation) after induction of pilocarpine-induced status epilepticus (SE) and before appearance of spontaneous seizure suggested the existence of sustained calpain activation during epileptogenesis. Acute treatment with a cell permeable inhibitor of calpain, MDL-28170, resulted in a partial but significant reduction on seizure burden. The reduction on seizure burden was associated with a limited reduction on the generation of SBDPs but was correlated with a reduction in astrocytosis, microglia activation and cell sprouting. Together, these observations provide evidence for the role of calpain in epileptogenesis. In addition, provide proof-of-principle for the use of calpain inhibitors as a novel strategy to prevent epileptic seizures and its associated pathologies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calpain; Epilepsy; Epileptogenesis; Proteolysis; Spontaneous seizures

Mesh:

Substances:

Year:  2017        PMID: 28237317      PMCID: PMC5640433          DOI: 10.1016/j.nbd.2017.02.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  58 in total

Review 1.  Calpain in the CNS: from synaptic function to neurotoxicity.

Authors:  Jing Liu; Ming Cheng Liu; Kevin K W Wang
Journal:  Sci Signal       Date:  2008-04-08       Impact factor: 8.192

Review 2.  Calpain as a therapeutic target in traumatic brain injury.

Authors:  Kathryn E Saatman; Jennifer Creed; Ramesh Raghupathi
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

3.  Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination.

Authors:  J A French; P D Williamson; V M Thadani; T M Darcey; R H Mattson; S S Spencer; D D Spencer
Journal:  Ann Neurol       Date:  1993-12       Impact factor: 10.422

4.  Hyperexcitability of the CA1 hippocampal region during epileptogenesis.

Authors:  Lynda El-Hassar; Monique Esclapez; Christophe Bernard
Journal:  Epilepsia       Date:  2007       Impact factor: 5.864

Review 5.  Neuroprotection in epilepsy.

Authors:  Matthew Walker
Journal:  Epilepsia       Date:  2007       Impact factor: 5.864

6.  Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia.

Authors:  P A Li; W Howlett; Q P He; H Miyashita; M Siddiqui; A Shuaib
Journal:  Neurosci Lett       Date:  1998-05-08       Impact factor: 3.046

7.  Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines.

Authors:  Anne A Kan; Wilco de Jager; Marina de Wit; Cobi Heijnen; Mirjam van Zuiden; Cyrill Ferrier; Peter van Rijen; Peter Gosselaar; Ellen Hessel; Onno van Nieuwenhuizen; Pierre N E de Graan
Journal:  J Neuroinflammation       Date:  2012-08-30       Impact factor: 8.322

8.  Calpain activity is essential in skin wound healing and contributes to scar formation.

Authors:  Dany Nassar; Emmanuel Letavernier; Laurent Baud; Selim Aractingi; Kiarash Khosrotehrani
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

9.  Occipital gamma activation during Vipassana meditation.

Authors:  B Rael Cahn; Arnaud Delorme; John Polich
Journal:  Cogn Process       Date:  2009-12-16

10.  Differential Activation of Calpain-1 and Calpain-2 following Kainate-Induced Seizure Activity in Rats and Mice.

Authors:  Jeff Seinfeld; Neema Baudry; Xiaobo Xu; Xiaoning Bi; Michel Baudry
Journal:  eNeuro       Date:  2016-09-06
View more
  9 in total

1.  Calpain activation and neuronal death during early epileptogenesis.

Authors:  Philip M Lam; Marco I González
Journal:  Neurobiol Dis       Date:  2018-11-10       Impact factor: 5.996

Review 2.  Calpain Inhibitors as Potential Therapeutic Modulators in Neurodegenerative Diseases.

Authors:  Heena Khan; Nikhil Garg; Thakur Gurjeet Singh; Amarjot Kaur; Komal Thapa
Journal:  Neurochem Res       Date:  2022-01-04       Impact factor: 3.996

3.  Calpain-dependent cleavage of GABAergic proteins during epileptogenesis.

Authors:  Marco I González
Journal:  Epilepsy Res       Date:  2019-09-17       Impact factor: 3.045

Review 4.  Altered GABAergic Signaling in Brain Disease at Various Stages of Life.

Authors:  Yoo Sung Kim; Bo-Eun Yoon
Journal:  Exp Neurobiol       Date:  2017-05-19       Impact factor: 3.261

Review 5.  Striatal Chloride Dysregulation and Impaired GABAergic Signaling Due to Cation-Chloride Cotransporter Dysfunction in Huntington's Disease.

Authors:  Melissa Serranilla; Melanie A Woodin
Journal:  Front Cell Neurosci       Date:  2022-01-14       Impact factor: 5.505

6.  Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus.

Authors:  Bryan S Barker; Jay Spampanato; Hilary S McCarren; Melissa Smolik; Cecelia E Jackson; Eden N Hornung; David T Yeung; F Edward Dudek; John H McDonough
Journal:  Neuroscience       Date:  2019-11-26       Impact factor: 3.708

Review 7.  Pathophysiology of Trans-Synaptic Adhesion Molecules: Implications for Epilepsy.

Authors:  Adam Gorlewicz; Leszek Kaczmarek
Journal:  Front Cell Dev Biol       Date:  2018-09-21

8.  M-Calpain Activation Facilitates Seizure Induced KCC2 Down Regulation.

Authors:  Li Wan; Liang Ren; Lulan Chen; Guoxiang Wang; Xu Liu; Benjamin H Wang; Yun Wang
Journal:  Front Mol Neurosci       Date:  2018-08-21       Impact factor: 5.639

9.  Calpain-2 as a Treatment Target in Prenatal Stress-induced Epileptic Spasms in Infant Rats.

Authors:  Hyeok Hee Kwon; Chiranjivi Neupane; Juhee Shin; Do Hyeong Gwon; Yuhua Yin; Nara Shin; Hyo Jung Shin; Jinpyo Hong; Jin Bong Park; YoonYoung Yi; Dong Woon Kim; Joon Won Kang
Journal:  Exp Neurobiol       Date:  2019-08-31       Impact factor: 3.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.